RxDoctor Payments Data

Michael Mercandetti, MD

Ophthalmic Plastic and Reconstructive Surgery · Venice, FLNPI 1669471959

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,072 and has fallen 95.7% since, to $46 in 2025. That places this record below the midpoint for ophthalmic plastic and reconstructive surgery clinicians in FL, where the typical reported total is $1,956.

$1,891in general payments, 2019–2025

Across 48 payments — averaging $39.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$353
  • Kerecis Limited$297
  • AbbVie$292
  • Amgen$251
  • ANI Pharmaceuticals, Inc.$165
  • Johnson & Johnson Surgical Vision, Inc.$147
  • plus $385 from 10 others

What the payments were for

  • Speaking & faculty fees$1257%
  • Food & beverage$1,76693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,891 in reported general payments places this provider in the 45th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.

See all ophthalmic plastic and reconstructive surgery providers in Florida

Medicare billing

Part B allowed, 2024
$318,977
Medicare patients
251
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha68$627
ErythromycinErythromycin Base63$563
Mupirocin14$43

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →